Abstract
Hypertension due to chronic inhibition of NO synthase (NOS) by Nω-nitro-L-arginine methyl ester (L-NAME) administration is characterized by both impaired NO-dependent vasodilation and enhanced sympathetic vasoconstriction. The aim of our study was to evaluate changes in the participation of major vasoactive systems in L-NAME–treated rats which were subjected to simultaneous antihypertensive (captopril) or antioxidant (N-acetylcysteine, NAC) treatment. Three-month-old Wistar males treated with L-NAME (60 mg/kg/day) for 5 weeks were compared to rats in which L-NAME treatment was combined with simultaneous chronic administration of captopril or NAC. Basal blood pressure (BP) and its acute responses to consecutive i.v. injections of captopril (10 mg/kg), pentolinium (5 mg/kg), L-NAME (30 mg/kg), tetraethylammonium (TEA, 16 mg/kg) and nitroprusside (NP, 20 μg/kg) were determined in conscious rats at the end of the study. The development of L-NAME hypertension was prevented by captopril treatment, whereas NAC treatment caused only a moderate BP reduction. Captopril treatment normalized the sympathetic BP component and significantly reduced residual BP (measured at full NP-induced vasodilation). In contrast, chronic NAC treatment did not modify the sympathetic BP component or residual BP, but significantly enhanced NO-dependent vasodilation. Neither captopril nor NAC treatment influenced the compensatory increase of TEA-sensitive vasodilation mediated by endothelium-derived hyperpolarizing factor in L-NAME–treated rats. Chronic captopril treatment prevented L-NAME hypertension by lowering of sympathetic tone, whereas chronic NAC treatment attenuated L-NAME hypertension by reduction in the vasodilator deficit due to enhanced NO-dependent vasodilation.
Similar content being viewed by others
Article PDF
References
Zanchi A, Schaad NC, Osterheld MC, et al: Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol 1995; 268: H2267–H2273.
Sander M, Victor RG : Neural mechanisms in nitric-oxide–deficient hypertension. Curr Opin Nephrol Hypertens 1999; 8: 61–73.
Henrion D, Dowell FJ, Levy BI, Michel JB : In vitro alteration of aortic vascular reactivity in hypertension induced by chronic NG-nitro-L-arginine methyl ester. Hypertension 1996; 28: 361–366.
Pecháňová O, Bernátová I, Pelouch V, Šimko F : Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol 1997; 29: 3365–3374.
Arnal JF, el Amrani AI, Chatellier G, Menard J, Michel JB : Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 1993; 22: 380–387.
Jover B, Herizi A, Ventre F, Dupont M, Mimran A : Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension 1993; 21: 944–948.
Sander M, Hansen J, Victor RG : The sympathetic nervous system is involved in the maintenance but not initiation of the hypertension induced by Nω-nitro-L-arginine methyl ester. Hypertension 1997; 30 ( Suppl I): 64–70.
Wangensteen R, O'Valle F, Del Moral R, Vargas F, Osuna A : Chronic α1-adrenergic blockade improves hypertension and renal injury in L-NAME and low-renin L-NAME–DOCA hypertensive rats. Med Sci Monit 2002; 8: BR378–BR384.
Gerová M, Török J, Pecháňová O, Matušková J : Rilmenidine prevents blood pressure increase in rats with compromised nitric oxide production. Acta Pharmacol Sin 2004; 25: 1640–1646.
Usui M, Egashira K, Tomita H, et al: Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101: 305–310.
Attia DM, Verhagen AM, Stroes ES, et al: Vitamin E alleviates renal injury, but not hypertension, during chronic nitric oxide synthase inhibition in rats. J Am Soc Nephrol 2001; 12: 2585–2593.
Rauchová H, Pecháňová O, Kuneš J, Vokurková M, Dobešová Z, Zicha J : Chronic N-acetylcysteine administration prevents development of hypertension in Nω-nitro-L-arginine methyl ester–treated rats: the role of reactive oxygen species. Hypertens Res 2005; 28: 475–482.
Zembowicz A, Hatchett RJ, Radziszewski W, Gryglewski RJ : Inhibition of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the inactivation by ebselen of a critical thiol essential for the catalytic activity of nitric oxide synthase. J Pharmacol Exp Ther 1993; 267: 1112–1118.
Myers PR, Minor RLJ, Guerra RJ, Bates JN, Harrison DG : Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 1990; 345: 161–163.
Pecháňová O, Dobešová Z, Čejka J, Kuneš J, Zicha J : Vasoactive systems in L-NAME hypertension: the role of inducible NO synthase. J Hypertens 2004; 22: 167–173.
Kuneš J, Miková D, Dobešová Z, Bíbová J, Hampl V, Zicha J : Vasodilatory mechanisms in L-NAME hypertension. Hypertension 2004; 44: 585 ( Abstract).
Minami N, Imai Y, Hashimoto J, Abe K : Contribution of vascular nitric oxide to basal blood pressure in conscious spontaneously hypertensive rats and normotensive Wistar Kyoto rats. Clin Sci 1995; 89: 177–182.
Berecek KH, Kirk KA, Nagahama S, Oparil S : Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril. Am J Physiol 1987; 252: H796–H806.
Kuneš J, Dobešová Z, Zicha J : Angiotensin-dependent sympathetic vasoconstriction in SHR: the effect of captopril treatment in young animals. J Hypertens 2005; 23 ( Suppl 2): S234 ( Abstract).
Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA : Sympatho-inhibitory properties of various AT1 receptor antagonists. J Hypertens 2002; 20 ( Suppl 5): S3–S11.
Ganten D, Hermann K, Bayer C, Unger T, Lang RE : Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science 1983; 221: 869–871.
Phillips MI, Kimura B : Brain angiotensin in the developing spontaneously hypertensive rat. J Hypertens 1988; 6: 607–612.
Krukoff TL : Central regulation of autonomic function: NO brakes? Clin Exp Pharmacol Physiol 1998; 25: 474–478.
Ye S, Zhong H, Duong VN, Campese VM : Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension 2002; 39: 1101–1106.
Campese VM, Ye S, Zhong H : Downregulation of neuronal nitric oxide synthase and interleukin-1β mediates angiotensin II–dependent stimulation of sympathetic nerve activity. Hypertension 2002; 39: 519–524.
Veerasingham SJ, Raizada MK : Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives. Br J Pharmacol 2003; 139: 191–202.
Nishimura M, Takahashi H, Nanbu A, Sakamoto M, Yoshimura M : Cardiovascular regulation by L-arginine in the brain of rats: role of the brain renin-angiotensin system and nitric oxide. Am J Hypertens 1997; 10: 389–396.
Sakima A, Teruya H, Yamazato M, Matayoshi R, Muratani H, Fukiyama K : Prolonged NOS inhibition in the brain elevates blood pressure in normotensive rats. Am J Physiol 1998; 275: R410–R417.
Tsuchihashi T, Kagiyama S, Matsumura K, Lin Y, Abe I, Fujishima M : Cardiovascular responses to glutamate and angiotensin II in ventrolateral medulla of hypertension induced by chronic inhibition of nitric oxide. Hypertens Res 2000; 23: 359–364.
Nakata T, Takeda K, Harada S, et al: Role of the central nervous system in the development of hypertension produced by chronic nitric oxide blockade in rats. Hypertens Res 2001; 24: 39–45.
Pecháňová O, Zicha J, Kojšová S, Dobešová Z, Jendeková L, Kuneš J : Effect of chronic N-acetylcysteine treatment on the development of spontaneous hypertension. Clin Sci 2006; 110: 235–242.
Vargas F, Osuna A, Fernandez-Rivas A : Vascular reactivity and flow-pressure curve in isolated kidneys from rats with N-nitro-L-arginine ester–induced hypertension. J Hypertens 1995; 14: 373–379.
Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R : Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 1996; 94: 3341–3347.
Kanematsu Y, Tsuchiya K, Ohnishi H, et al: Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in N-nitro-L-arginine methyl ester–treated rats. Hypertens Res 2006; 29: 369–374.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zicha, J., Dobešová, Z. & Kuneš, J. Antihypertensive Mechanisms of Chronic Captopril or N-Acetylcysteine Treatment in L-NAME Hypertensive Rats. Hypertens Res 29, 1021–1027 (2006). https://doi.org/10.1291/hypres.29.1021
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.29.1021
Keywords
This article is cited by
-
N-Acetylcysteine: more than preventing contrast-induced nephropathy in uremic patients—focus on the antioxidant and anti-inflammatory properties
International Urology and Nephrology (2023)
-
Toxicity Study of 3-Thienylalanine- Ornithine-Proline (TOP) Using as Novel ACE Inhibitor
International Journal of Peptide Research and Therapeutics (2022)
-
Hypotensive and antihypertensive effects of an aqueous extract from Guinep fruit (Melicoccus bijugatus Jacq) in rats
Scientific Reports (2020)
-
Acute and chronic antihypertensive effects of Cinnamomum zeylanicum stem bark methanol extract in L-NAME-induced hypertensive rats
BMC Complementary and Alternative Medicine (2013)
-
The renoprotective effect of l-carnitine in hypertensive rats is mediated by modulation of oxidative stress-related gene expression
European Journal of Nutrition (2013)